A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

Inclusion Criteria:

- Patients must have a histologically or cytologically confirmed cancer diagnosis for
which EGFRI treatment is indicated

- Initiation of topical steroids or control treatment within 3 days of initiation of
cetuximab, erlotinib, panitumumab, or afatinib

- Patients must be age ≥ 18 years.

- Life expectancy of greater than 6 weeks

- Patient able to use topical medications reliably and complete questionnaires with
assistance if needed

- Patients must have the ability to understand and the willingness to sign a written
informed consent prior to registration on study.

Exclusion Criteria:

- Patients who have used systemic or topical steroids within 7 days of trial
registration, or start systemic or topical steroids for reasons unrelated to trial
during the 6-week follow up period

- Patients who have used antibiotics within 7 days of trial registration, or start
antibiotics for other conditions during the 6-week follow up period

- History of allergic reactions to topical steroids

- Patients with any rash at the time of study registration

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Patients using any other topical medications in the treatment areas (face, chest, or
back).